Breast Cancer Clinical Trial
Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
Summary
PROGECT is a registry for patients with Triple Negative breast cancer (TNBC) or patients who have an identified germline mutations (such as a mutation on the BRCA1 or BRCA2 genes).
Full Description
This study is being done to collect cancer-related information from patients with triple negative breast cancer and patients with hereditary genetic mutations. This information will help us better understand the link between genetic changes and cancer outcome in patients with triple negative breast cancer.
Eligibility Criteria
Inclusion criteria include:
Triple Negative Breast Cancer
ER/PR <10% and HER negative per current ASCO/CAP guidelines
Stages I-IV
Any age at diagnosis
Patient must be within 5 years of diagnosis
Eligible regardless of genetic testing status
Genetic testing recommended for patients meeting NCCN and Medicare guidelines
AND/OR
Germline mutation Carriers
Patients with deleterious or uncertain mutations in HBOC genes (BRCA, PTEN, P53, -PALB2 etc) are eligible regardless of type/site of cancer
Healthy patients harboring mutations also eligible
There is no time limit from the time of diagnosis of cancer and enrollment.
Eligible regardless of personal history of cancer
Exclusion Criteria include:
Triple Negative Breast Cancer -Patient is not within five years of diagnosis
Germline mutation Carriers:
-Patient only carries a HBOC mutation that is classified as "polymorphism" of "favor polymorphism"
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 13 Locations for this study
Salina Kansas, 67401, United States More Info
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.